In the BioHarmony Drug Report Database

"Preview" Icon

Filgotinib

Jyseleca (filgotinib) is a small molecule pharmaceutical. Filgotinib was first approved as Jyseleca on 2020-09-24. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1. In addition, it is known to target tyrosine-protein kinase JAK3, non-receptor tyrosine-protein kinase TYK2, and tyrosine-protein kinase JAK2.

 

Trade Name

 

Jyseleca
 

Common Name

 

filgotinib
 

ChEMBL ID

 

CHEMBL3301607
 

Indication

 

rheumatoid arthritis
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Filgotinib structure rendering